You are here

Share:

Search Technologies

Showing 61-80 of 198 results found

Novel Anti-HIV Proteins from Coral Reefs

Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of cnidarins.

Non-invasive Methods for Characterizing Adrenocortical Tumors

Researchers at the NCI developed a non-invasive method for distinguishing benign from malignant adrenocortical tumors using urine samples. The NCI seeks parties to co-develop a non-invasive, diagnostic method of distinguishing between benign and malignant adrenocortical tumors through the analysis of metabolites using urine samples.

Non-Invasive In Vivo MRI Method to Image Salient Features of Axons and Nerves

Scientists from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have developed a novel diffusion Magnetic Resonance Imaging (MRI) experimental and modeling framework to measure new and useful microanatomical features of white matter (and gray matter), which are closely related to the function of the central nervous system (CNS) or peripheral nervous system (PNS). This invention is available for licensing or co-development partners.

Niclosamide for Treating Adrenocortical Cancer (ACC)

Researchers at the NCI have developed a novel treatment for adrenocortical cancer (ACC) by repositioning the drug niclosamide. New treatments for ACC can help patients with this rare and aggressive disease, where the current standard of care involves highly toxic options. The NCI seeks parties to license this method of treating adrenocortical cancer using niclosamide.

New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies

Researchers at the National Cancer Institute (NCI) have developed a new format for expressing Chimeric Antigen Receptors (CARs) that is available for licensing and co-development. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. The novel technology is useful for improving CAR therapies to treat a range of cancers.

Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors

Researchers at the National Cancer Institute (NCI) developed novel groups of cyanine (Cy) based antibody-drug conjugate (ADC) chemical linkers that undergo photolytic cleavage upon irradiation with near-IR light. By using the fluorescent properties of the Cy linker to monitor localization of the ADC, and subsequent near-IR irradiation of cancerous tissue, drug release could be confined to the tumor microenvironment.

Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery

The National Cancer Institute (NCI) seeks research a co-development partner and/or licensees for applications utilizing the nanoparticle platform technology for delivery of cancer-specific microRNAs, particularly for therapeutic uses in surface cancers, such as mesothelioma.

Nanoparticle delivery of lung cancer therapeutic

The National Cancer Institute seeks parties interested in licensing an improved treatment for non-small cell lung cancer based on inhalation of nano- and microparticle therapeutics.

Murine metastatic pancreatic adenocarcinoma cell lines

Researchers at the National Cancer Institute (NCI) developed orthotopic allograft models for pancreatic cancer that utilize cells or tumor fragments implanted into the cancer-free pancreata of recipient immunocompetent mice. NCI seeks licensees to commercialize this invention.

Multivalent Immunogenic Vaccines for Treating Prostate and Breast Cancer

Researchers at the NCI have developed a treatment for prostate and breast cancer using multivalent peptides derived from TARP, the T cell receptor gamma alternate reading frame protein. These immunogenic peptides from TARP elicit an immune response, triggering T cells to kill only the cancer cells within a patient. NCI seeks licensees or co-development partners to commercialize this invention.

Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics

The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present technology discloses novel RNA  and RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. The National Cancer Institute sees parties interested licensing this technology  or in collaborative research to co-develop RNAi-based nanoparticle therapeutics for cancer and HIV.

MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury

Researchers at the NICHD developed a method for non-invasively determining the distribution of pore lengths and radii within a matrix thereby characterizing cognitive defects observed in patients with Traumatic Brain Injury (TBI). The NICHD seeks licensing and/or co-development research collaborations to bring this invention to the public.

Mouse Xenograft Model for Mesothelioma

The National Cancer Institute is seeking parties interested in collaborative research to co-develop, evaluate, or commercialize a new mouse model for monoclonal antibodies and immunoconjugates that target malignant mesotheliomas. Applications of the technology include models for screening compounds as potential therapeutics for mesothelioma and for studying the pathology of mesothelioma.

Pages